1
|
Zamecnik CR, Sowa GM, Abdelhak A, Dandekar R, Bair RD, Wade KJ, Bartley CM, Kizer K, Augusto DG, Tubati A, Gomez R, Fouassier C, Gerungan C, Caspar CM, Alexander J, Wapniarski AE, Loudermilk RP, Eggers EL, Zorn KC, Ananth K, Jabassini N, Mann SA, Ragan NR, Santaniello A, Henry RG, Baranzini SE, Zamvil SS, Sabatino JJ, Bove RM, Guo CY, Gelfand JM, Cuneo R, von Büdingen HC, Oksenberg JR, Cree BAC, Hollenbach JA, Green AJ, Hauser SL, Wallin MT, DeRisi JL, Wilson MR. An autoantibody signature predictive for multiple sclerosis. Nat Med 2024:10.1038/s41591-024-02938-3. [PMID: 38641750 DOI: 10.1038/s41591-024-02938-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2023] [Accepted: 03/21/2024] [Indexed: 04/21/2024]
Abstract
Although B cells are implicated in multiple sclerosis (MS) pathophysiology, a predictive or diagnostic autoantibody remains elusive. In this study, the Department of Defense Serum Repository (DoDSR), a cohort of over 10 million individuals, was used to generate whole-proteome autoantibody profiles of hundreds of patients with MS (PwMS) years before and subsequently after MS onset. This analysis defines a unique cluster in approximately 10% of PwMS who share an autoantibody signature against a common motif that has similarity with many human pathogens. These patients exhibit antibody reactivity years before developing MS symptoms and have higher levels of serum neurofilament light (sNfL) compared to other PwMS. Furthermore, this profile is preserved over time, providing molecular evidence for an immunologically active preclinical period years before clinical onset. This autoantibody reactivity was validated in samples from a separate incident MS cohort in both cerebrospinal fluid and serum, where it is highly specific for patients eventually diagnosed with MS. This signature is a starting point for further immunological characterization of this MS patient subset and may be clinically useful as an antigen-specific biomarker for high-risk patients with clinically or radiologically isolated neuroinflammatory syndromes.
Collapse
Affiliation(s)
- Colin R Zamecnik
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Gavin M Sowa
- University of California, San Francisco School of Medicine, San Francisco, CA, USA
- Department of Medicine, McGaw Medical Center of Northwestern University, Chicago, IL, USA
| | - Ahmed Abdelhak
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Ravi Dandekar
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Rebecca D Bair
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Kristen J Wade
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Christopher M Bartley
- Department of Psychiatry and Behavioral Sciences, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Kerry Kizer
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Danillo G Augusto
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
- Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC, USA
| | - Asritha Tubati
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Refujia Gomez
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Camille Fouassier
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Chloe Gerungan
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Colette M Caspar
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Jessica Alexander
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Anne E Wapniarski
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Rita P Loudermilk
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Erica L Eggers
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Kelsey C Zorn
- Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA
| | - Kirtana Ananth
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Nora Jabassini
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Sabrina A Mann
- Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA
- Chan Zuckerberg Biohub San Francisco, San Francisco, CA, USA
| | - Nicholas R Ragan
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Adam Santaniello
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Roland G Henry
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Sergio E Baranzini
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Scott S Zamvil
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Joseph J Sabatino
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Riley M Bove
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Chu-Yueh Guo
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Jeffrey M Gelfand
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Richard Cuneo
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - H-Christian von Büdingen
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Jorge R Oksenberg
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Bruce A C Cree
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Jill A Hollenbach
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
- Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA
| | - Ari J Green
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Stephen L Hauser
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Mitchell T Wallin
- Department of Veterans Affairs, Multiple Sclerosis Center of Excellence, Washington, DC, USA
- University of Maryland School of Medicine, Baltimore, MD, USA
| | - Joseph L DeRisi
- Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA
- Chan Zuckerberg Biohub San Francisco, San Francisco, CA, USA
| | - Michael R Wilson
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
| |
Collapse
|
2
|
Bartley CM, Ngo TT, Duy Do L, Zekeridou A, Dandekar R, Muñiz-Castrillo S, Alvarenga BD, Zorn KC, Tubati A, Pinto AL, Browne WD, Hullett PW, Terrelonge M, Schubert RD, Piquet AL, Yang B, Montalvo Perero MJ, Kung AF, Mann SA, Shah MP, Geschwind MD, Gelfand JM, DeRisi JL, Pittock SJ, Honnorat J, Pleasure SJ, Wilson MR. Detection of High-Risk Paraneoplastic Antibodies against TRIM9 and TRIM67 Proteins. Ann Neurol 2023; 94:1086-1101. [PMID: 37632288 PMCID: PMC10842626 DOI: 10.1002/ana.26776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Revised: 08/22/2023] [Accepted: 08/22/2023] [Indexed: 08/27/2023]
Abstract
OBJECTIVE Co-occurring anti-tripartite motif-containing protein 9 and 67 autoantibodies (TRIM9/67-IgG) have been reported in only a very few cases of paraneoplastic cerebellar syndrome. The value of these biomarkers and the most sensitive methods of TRIM9/67-IgG detection are not known. METHODS We performed a retrospective, multicenter study to evaluate the cerebrospinal fluid and serum of candidate TRIM9/67-IgG cases by tissue-based immunofluorescence, peptide phage display immunoprecipitation sequencing, overexpression cell-based assay (CBA), and immunoblot. Cases in which TRIM9/67-IgG was detected by at least 2 assays were considered TRIM9/67-IgG positive. RESULTS Among these cases (n = 13), CBA was the most sensitive (100%) and revealed that all cases had TRIM9 and TRIM67 autoantibodies. Of TRIM9/67-IgG cases with available clinical history, a subacute cerebellar syndrome was the most common presentation (n = 7/10), followed by encephalitis (n = 3/10). Of these 10 patients, 70% had comorbid cancer (7/10), 85% of whom (n = 6/7) had confirmed metastatic disease. All evaluable cancer biopsies expressed TRIM9 protein (n = 5/5), whose expression was elevated in the cancerous regions of the tissue in 4 of 5 cases. INTERPRETATION TRIM9/67-IgG is a rare but likely high-risk paraneoplastic biomarker for which CBA appears to be the most sensitive diagnostic assay. ANN NEUROL 2023;94:1086-1101.
Collapse
Affiliation(s)
- Christopher M. Bartley
- Weill Institute for Neurosciences, University of California, San Francisco, California
- Department of Psychiatry and Behavioral Sciences, University of California San Francisco, California
| | - Thomas T. Ngo
- Weill Institute for Neurosciences, University of California, San Francisco, California
- Department of Psychiatry and Behavioral Sciences, University of California San Francisco, California
- Department of Neurology, University of California, San Francisco, California
| | - Le Duy Do
- French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon and SynatAc Team, Institut MELiS, INSERM U1314/CNRS UMR 5284, Universités de Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - Anastasia Zekeridou
- Department of Neurology, Center MS and Autoimmune Neurology, Mayo Clinic
- Department of Laboratory Medicine and Pathology, Mayo Clinic
| | - Ravi Dandekar
- Weill Institute for Neurosciences, University of California, San Francisco, California
- Department of Neurology, University of California, San Francisco, California
| | - Sergio Muñiz-Castrillo
- French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon and SynatAc Team, Institut MELiS, INSERM U1314/CNRS UMR 5284, Universités de Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - Bonny D. Alvarenga
- Weill Institute for Neurosciences, University of California, San Francisco, California
- Department of Neurology, University of California, San Francisco, California
| | - Kelsey C. Zorn
- Department of Biochemistry and Biophysics, University of California, San Francisco, California
| | - Asritha Tubati
- Weill Institute for Neurosciences, University of California, San Francisco, California
- Department of Neurology, University of California, San Francisco, California
| | - Anne-Laurie Pinto
- French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon and SynatAc Team, Institut MELiS, INSERM U1314/CNRS UMR 5284, Universités de Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - Weston D. Browne
- Weill Institute for Neurosciences, University of California, San Francisco, California
- Department of Neurology, University of California, San Francisco, California
| | - Patrick W. Hullett
- Weill Institute for Neurosciences, University of California, San Francisco, California
- Department of Neurology, University of California, San Francisco, California
| | - Mark Terrelonge
- Weill Institute for Neurosciences, University of California, San Francisco, California
- Department of Neurology, University of California, San Francisco, California
| | - Ryan D. Schubert
- Weill Institute for Neurosciences, University of California, San Francisco, California
- Department of Neurology, University of California, San Francisco, California
| | - Amanda L. Piquet
- Department of Neurology, University of Colorado Anschutz Medical Campus, School of Medicine, Aurora, Colorado
| | - Binxia Yang
- Department of Laboratory Medicine and Pathology, Mayo Clinic
| | | | - Andrew F. Kung
- University of California San Francisco, School of Medicine, San Francisco, California
| | - Sabrina A. Mann
- Chan Zuckerberg Biohub, San Francisco, California
- Department of Biochemistry and Biophysics, University of California, San Francisco, California
| | - Maulik P. Shah
- Weill Institute for Neurosciences, University of California, San Francisco, California
- Department of Neurology, University of California, San Francisco, California
| | - Michael D. Geschwind
- Weill Institute for Neurosciences, University of California, San Francisco, California
- Department of Neurology, University of California, San Francisco, California
| | - Jeffrey M. Gelfand
- Weill Institute for Neurosciences, University of California, San Francisco, California
- Department of Neurology, University of California, San Francisco, California
| | - Joseph L. DeRisi
- Chan Zuckerberg Biohub, San Francisco, California
- Department of Biochemistry and Biophysics, University of California, San Francisco, California
| | - Sean J. Pittock
- Department of Neurology, Center MS and Autoimmune Neurology, Mayo Clinic
- Department of Laboratory Medicine and Pathology, Mayo Clinic
| | - Jérôme Honnorat
- French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon and SynatAc Team, Institut MELiS, INSERM U1314/CNRS UMR 5284, Universités de Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - Samuel J. Pleasure
- Weill Institute for Neurosciences, University of California, San Francisco, California
- Department of Neurology, University of California, San Francisco, California
| | - Michael R. Wilson
- Weill Institute for Neurosciences, University of California, San Francisco, California
- Department of Neurology, University of California, San Francisco, California
| |
Collapse
|
3
|
Rolfes M, Harroud A, Zorn KC, Tubati A, Omura C, Kurtz K, Matloubian M, Berger A, Chiu CY, Wilson MR, Ramachandran PS. Complement Factor I Gene Variant as a Treatable Cause of Recurrent Aseptic Neutrophilic Meningitis: A Case Report. Neurol Neuroimmunol Neuroinflamm 2023; 10:e200121. [PMID: 37339889 DOI: 10.1212/nxi.0000000000200121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/22/2022] [Accepted: 03/10/2023] [Indexed: 06/22/2023]
Abstract
Mutations in the complement factor I (CFI) gene have previously been identified as causes of recurrent CNS inflammation. We present a case of a 26-year-old man with 18 episodes of recurrent meningitis, who had a variant in CFI(c.859G>A,p.Gly287Arg) not previously associated with neurologic manifestations. He achieved remission with canakinumab, a human monoclonal antibody targeted at interleukin-1 beta.
Collapse
Affiliation(s)
- Mary Rolfes
- From the Weill Institute for Neurosciences (M.R., M.R.W.), Department of Neurology, University of California, San Francisco; Montreal Neurological Institute and Hospital (A.H.), Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada; Department of Biochemistry and Biophysics (K.C.Z., A.T.); Department of Laboratory Medicine (C.O., C.Y.C.); Kaiser Permanente Santa Rosa Medical Center (K.K.)Department of Medicine (M.M.), Division of Rheumatology; Department of Medicine (A.B.), Molecular Medicine Consult Service; Department of Medicine (C.Y.C.), Division of Infectious Diseases, University of California, San Francisco; The Peter Doherty Institute for Infection and Immunity (P.S.R.); Department of Neurology (P.S.R.), Royal Melbourne Hospital; and Department of Neurology (P.S.R.), St.Vincent's Hospital, University of Melbourne, Australia
| | - Adil Harroud
- From the Weill Institute for Neurosciences (M.R., M.R.W.), Department of Neurology, University of California, San Francisco; Montreal Neurological Institute and Hospital (A.H.), Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada; Department of Biochemistry and Biophysics (K.C.Z., A.T.); Department of Laboratory Medicine (C.O., C.Y.C.); Kaiser Permanente Santa Rosa Medical Center (K.K.)Department of Medicine (M.M.), Division of Rheumatology; Department of Medicine (A.B.), Molecular Medicine Consult Service; Department of Medicine (C.Y.C.), Division of Infectious Diseases, University of California, San Francisco; The Peter Doherty Institute for Infection and Immunity (P.S.R.); Department of Neurology (P.S.R.), Royal Melbourne Hospital; and Department of Neurology (P.S.R.), St.Vincent's Hospital, University of Melbourne, Australia
| | - Kelsey C Zorn
- From the Weill Institute for Neurosciences (M.R., M.R.W.), Department of Neurology, University of California, San Francisco; Montreal Neurological Institute and Hospital (A.H.), Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada; Department of Biochemistry and Biophysics (K.C.Z., A.T.); Department of Laboratory Medicine (C.O., C.Y.C.); Kaiser Permanente Santa Rosa Medical Center (K.K.)Department of Medicine (M.M.), Division of Rheumatology; Department of Medicine (A.B.), Molecular Medicine Consult Service; Department of Medicine (C.Y.C.), Division of Infectious Diseases, University of California, San Francisco; The Peter Doherty Institute for Infection and Immunity (P.S.R.); Department of Neurology (P.S.R.), Royal Melbourne Hospital; and Department of Neurology (P.S.R.), St.Vincent's Hospital, University of Melbourne, Australia
| | - Asritha Tubati
- From the Weill Institute for Neurosciences (M.R., M.R.W.), Department of Neurology, University of California, San Francisco; Montreal Neurological Institute and Hospital (A.H.), Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada; Department of Biochemistry and Biophysics (K.C.Z., A.T.); Department of Laboratory Medicine (C.O., C.Y.C.); Kaiser Permanente Santa Rosa Medical Center (K.K.)Department of Medicine (M.M.), Division of Rheumatology; Department of Medicine (A.B.), Molecular Medicine Consult Service; Department of Medicine (C.Y.C.), Division of Infectious Diseases, University of California, San Francisco; The Peter Doherty Institute for Infection and Immunity (P.S.R.); Department of Neurology (P.S.R.), Royal Melbourne Hospital; and Department of Neurology (P.S.R.), St.Vincent's Hospital, University of Melbourne, Australia
| | - Charles Omura
- From the Weill Institute for Neurosciences (M.R., M.R.W.), Department of Neurology, University of California, San Francisco; Montreal Neurological Institute and Hospital (A.H.), Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada; Department of Biochemistry and Biophysics (K.C.Z., A.T.); Department of Laboratory Medicine (C.O., C.Y.C.); Kaiser Permanente Santa Rosa Medical Center (K.K.)Department of Medicine (M.M.), Division of Rheumatology; Department of Medicine (A.B.), Molecular Medicine Consult Service; Department of Medicine (C.Y.C.), Division of Infectious Diseases, University of California, San Francisco; The Peter Doherty Institute for Infection and Immunity (P.S.R.); Department of Neurology (P.S.R.), Royal Melbourne Hospital; and Department of Neurology (P.S.R.), St.Vincent's Hospital, University of Melbourne, Australia
| | - Kenneth Kurtz
- From the Weill Institute for Neurosciences (M.R., M.R.W.), Department of Neurology, University of California, San Francisco; Montreal Neurological Institute and Hospital (A.H.), Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada; Department of Biochemistry and Biophysics (K.C.Z., A.T.); Department of Laboratory Medicine (C.O., C.Y.C.); Kaiser Permanente Santa Rosa Medical Center (K.K.)Department of Medicine (M.M.), Division of Rheumatology; Department of Medicine (A.B.), Molecular Medicine Consult Service; Department of Medicine (C.Y.C.), Division of Infectious Diseases, University of California, San Francisco; The Peter Doherty Institute for Infection and Immunity (P.S.R.); Department of Neurology (P.S.R.), Royal Melbourne Hospital; and Department of Neurology (P.S.R.), St.Vincent's Hospital, University of Melbourne, Australia
| | - Mehrdad Matloubian
- From the Weill Institute for Neurosciences (M.R., M.R.W.), Department of Neurology, University of California, San Francisco; Montreal Neurological Institute and Hospital (A.H.), Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada; Department of Biochemistry and Biophysics (K.C.Z., A.T.); Department of Laboratory Medicine (C.O., C.Y.C.); Kaiser Permanente Santa Rosa Medical Center (K.K.)Department of Medicine (M.M.), Division of Rheumatology; Department of Medicine (A.B.), Molecular Medicine Consult Service; Department of Medicine (C.Y.C.), Division of Infectious Diseases, University of California, San Francisco; The Peter Doherty Institute for Infection and Immunity (P.S.R.); Department of Neurology (P.S.R.), Royal Melbourne Hospital; and Department of Neurology (P.S.R.), St.Vincent's Hospital, University of Melbourne, Australia
| | - Amy Berger
- From the Weill Institute for Neurosciences (M.R., M.R.W.), Department of Neurology, University of California, San Francisco; Montreal Neurological Institute and Hospital (A.H.), Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada; Department of Biochemistry and Biophysics (K.C.Z., A.T.); Department of Laboratory Medicine (C.O., C.Y.C.); Kaiser Permanente Santa Rosa Medical Center (K.K.)Department of Medicine (M.M.), Division of Rheumatology; Department of Medicine (A.B.), Molecular Medicine Consult Service; Department of Medicine (C.Y.C.), Division of Infectious Diseases, University of California, San Francisco; The Peter Doherty Institute for Infection and Immunity (P.S.R.); Department of Neurology (P.S.R.), Royal Melbourne Hospital; and Department of Neurology (P.S.R.), St.Vincent's Hospital, University of Melbourne, Australia
| | - Charles Y Chiu
- From the Weill Institute for Neurosciences (M.R., M.R.W.), Department of Neurology, University of California, San Francisco; Montreal Neurological Institute and Hospital (A.H.), Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada; Department of Biochemistry and Biophysics (K.C.Z., A.T.); Department of Laboratory Medicine (C.O., C.Y.C.); Kaiser Permanente Santa Rosa Medical Center (K.K.)Department of Medicine (M.M.), Division of Rheumatology; Department of Medicine (A.B.), Molecular Medicine Consult Service; Department of Medicine (C.Y.C.), Division of Infectious Diseases, University of California, San Francisco; The Peter Doherty Institute for Infection and Immunity (P.S.R.); Department of Neurology (P.S.R.), Royal Melbourne Hospital; and Department of Neurology (P.S.R.), St.Vincent's Hospital, University of Melbourne, Australia
| | - Michael R Wilson
- From the Weill Institute for Neurosciences (M.R., M.R.W.), Department of Neurology, University of California, San Francisco; Montreal Neurological Institute and Hospital (A.H.), Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada; Department of Biochemistry and Biophysics (K.C.Z., A.T.); Department of Laboratory Medicine (C.O., C.Y.C.); Kaiser Permanente Santa Rosa Medical Center (K.K.)Department of Medicine (M.M.), Division of Rheumatology; Department of Medicine (A.B.), Molecular Medicine Consult Service; Department of Medicine (C.Y.C.), Division of Infectious Diseases, University of California, San Francisco; The Peter Doherty Institute for Infection and Immunity (P.S.R.); Department of Neurology (P.S.R.), Royal Melbourne Hospital; and Department of Neurology (P.S.R.), St.Vincent's Hospital, University of Melbourne, Australia
| | - Prashanth S Ramachandran
- From the Weill Institute for Neurosciences (M.R., M.R.W.), Department of Neurology, University of California, San Francisco; Montreal Neurological Institute and Hospital (A.H.), Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada; Department of Biochemistry and Biophysics (K.C.Z., A.T.); Department of Laboratory Medicine (C.O., C.Y.C.); Kaiser Permanente Santa Rosa Medical Center (K.K.)Department of Medicine (M.M.), Division of Rheumatology; Department of Medicine (A.B.), Molecular Medicine Consult Service; Department of Medicine (C.Y.C.), Division of Infectious Diseases, University of California, San Francisco; The Peter Doherty Institute for Infection and Immunity (P.S.R.); Department of Neurology (P.S.R.), Royal Melbourne Hospital; and Department of Neurology (P.S.R.), St.Vincent's Hospital, University of Melbourne, Australia.
| |
Collapse
|
4
|
Zamecnik CR, Sowa GM, Abdelhak A, Dandekar R, Bair RD, Wade KJ, Bartley CM, Tubati A, Gomez R, Fouassier C, Gerungan C, Alexander J, Wapniarski AE, Loudermilk RP, Eggers EL, Zorn KC, Ananth K, Jabassini N, Mann SA, Ragan NR, Santaniello A, Henry RG, Baranzini SE, Zamvil SS, Bove RM, Guo CY, Gelfand JM, Cuneo R, von Büdingen HC, Oksenberg JR, Cree BAC, Hollenbach JA, Green AJ, Hauser SL, Wallin MT, DeRisi JL, Wilson MR. A Predictive Autoantibody Signature in Multiple Sclerosis. medRxiv 2023:2023.05.01.23288943. [PMID: 37205595 PMCID: PMC10187343 DOI: 10.1101/2023.05.01.23288943] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
Abstract
Although B cells are implicated in multiple sclerosis (MS) pathophysiology, a predictive or diagnostic autoantibody remains elusive. Here, the Department of Defense Serum Repository (DoDSR), a cohort of over 10 million individuals, was used to generate whole-proteome autoantibody profiles of hundreds of patients with MS (PwMS) years before and subsequently after MS onset. This analysis defines a unique cluster of PwMS that share an autoantibody signature against a common motif that has similarity with many human pathogens. These patients exhibit antibody reactivity years before developing MS symptoms and have higher levels of serum neurofilament light (sNfL) compared to other PwMS. Furthermore, this profile is preserved over time, providing molecular evidence for an immunologically active prodromal period years before clinical onset. This autoantibody reactivity was validated in samples from a separate incident MS cohort in both cerebrospinal fluid (CSF) and serum, where it is highly specific for patients eventually diagnosed with MS. This signature is a starting point for further immunological characterization of this MS patient subset and may be clinically useful as an antigen-specific biomarker for high-risk patients with clinically- or radiologically-isolated neuroinflammatory syndromes.
Collapse
Affiliation(s)
- Colin R. Zamecnik
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| | - Gavin M. Sowa
- Department of Medicine, McGaw Medical Center of Northwestern University, Chicago, IL, USA
| | - Ahmed Abdelhak
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| | - Ravi Dandekar
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| | - Rebecca D. Bair
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| | - Kristen J. Wade
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| | - Christopher M. Bartley
- UCSF Weill Institute for Neurosciences, Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA, USA
| | - Asritha Tubati
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| | - Refujia Gomez
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| | - Camille Fouassier
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| | - Chloe Gerungan
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| | - Jessica Alexander
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| | - Anne E. Wapniarski
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| | - Rita P. Loudermilk
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| | - Erica L. Eggers
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| | - Kelsey C. Zorn
- Department of Biochemistry and Biophysics, University of California, San Francisco, CA, USA
| | - Kirtana Ananth
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| | - Nora Jabassini
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| | - Sabrina A. Mann
- Department of Biochemistry and Biophysics, University of California, San Francisco, CA, USA
| | - Nicholas R. Ragan
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| | - Adam Santaniello
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| | - Roland G. Henry
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| | - Sergio E. Baranzini
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| | - Scott S. Zamvil
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| | - Riley M. Bove
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| | - Chu-Yueh Guo
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| | - Jeffrey M. Gelfand
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| | - Richard Cuneo
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| | - H.-Christian von Büdingen
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| | - Jorge R. Oksenberg
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| | - Bruce AC Cree
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| | - Jill A. Hollenbach
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
- Department of Epidemiology and Biostatistics, University of California, San Francisco, CA USA
| | - Ari J. Green
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| | - Stephen L. Hauser
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| | - Mitchell T. Wallin
- Veterans Affairs, Multiple Sclerosis Center of Excellence, Washington, DC and University of Maryland School of Medicine, Baltimore, MD, USA
| | - Joseph L. DeRisi
- Department of Biochemistry and Biophysics, University of California, San Francisco, CA, USA
- Chan Zuckerberg Biohub, San Francisco, CA, USA
| | - Michael R. Wilson
- UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA
| |
Collapse
|